Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: Neuronal loss, a key substrate of irreversible disability in multiple sclerosis (MS), is a recognized feature of MS cortical pathology of which the cause remains unknown. Fibrin(ogen) deposition is neurotoxic in animal models of MS, but has not been evaluated in human progressive MS cortex. The aim of this study was to investigate the extent and distribution of fibrin(ogen) in progressive MS cortex and elucidate its relationship with neurodegeneration. Methods: A postmortem cohort of pathologically confirmed MS (n = 47) and control (n = 10) cases was used. The extent and distribution of fibrin(ogen) was assessed and related to measures of demyelination, inflammation, and neuronal density. In a subset of cases (MS, n = 20; control, n = 10), expression of plasminogen activator inhibitor 1 (PAI‐1), a key enzyme in the fibrinolytic cascade, was assessed and related to the extent of fibrin(ogen). Results: Motor cortical fibrin(ogen) deposition was significantly over‐represented in MS compared to control cases in all compartments studied (ie, extracellular [p = 0.001], cell body [p = 0.003], and neuritic/glial‐processes [p = 0.004]). MS cases with high levels of extracellular fibrin(ogen) had significantly upregulated PAI‐1 expression in all cortical layers assessed (p < 0.05) and reduced neuronal density (p = 0.017), including in the functionally‐relevant layer 5 (p = 0.001). Interpretation: For the first time, we provide unequivocal evidence that fibrin(ogen) is extensively deposited in progressive MS motor cortex, where regulation of fibrinolysis appears perturbed. Progressive MS cases with severe fibrin(ogen) deposition have significantly reduced neuronal density. Future studies are needed to elucidate the provenance and putative neurotoxicity of fibrin(ogen), and its potential impact on clinical disability. Ann Neurol 2017;82:259–270
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033 · cited 1×
“A widely held theory states that the progressive stage of MS is characterized by compartmentalization of central nervous system (CNS) inflammation behind an intact blood– brain barrier (BBB).(2) According to this view, the inaccessibility of the CNS in progressive disease might explain why immunomodulatory compounds f…”
BackgroundA Gradient of neuronal loss and meningeal inflammation in multiple sclerosis
Magliozzi, R., Howell, O. W., Reeves, C., Roncaroli, F., Nicholas, R., Serafini, B., Aloisi, F., & Reynolds, R. (2010) · Annals of Neurology · doi:10.1002/ana.22230 · Cited by 747
The cortical angiome: an interconnected vascular network with noncolumnar patterns of blood flow
Blinder, P., Tsai, P. S., Kaufhold, J. P., Knutsen, P. M., Suhl, H., & Kleinfeld, D. (2013) · Nature Neuroscience · doi:10.1038/nn.3426 · Cited by 573
Adams, R. A., Bauer, J., Flick, M. J., Sikorski, S. L., Nuriel, T., Lassmann, H., Degen, J. L., & Akassoglou, K. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061931 · Cited by 335
Disease-specific molecular events in cortical multiple sclerosis lesions
Fischer, M. T., Wimmer, I., Höftberger, R., Gerlach, S., Haider, L., Zrzavy, T., Hametner, S., Mahad, D., Binder, C. J., Krumbholz, M., et al. (2013) · Brain · doi:10.1093/brain/awt110 · Cited by 311
Ryu, J. K., Petersen, M. A., Murray, S. G., Baeten, K. M., Meyer-Franke, A., Chan, J. P., Vagena, E., Bedard, C., Machado, M. R., Coronado, P. E. R., et al. (2015) · Nature Communications · doi:10.1038/ncomms9164 · Cited by 271 · cited 1×
“In experimental autoimmune encephalomyelitis (EAE), fibrinogen extravasation induces activation of microglia and subsequent axonal damage before onset of clinical signs, as well as promoting recruitment of myelin specific T cells.(8,9) Blocking the interaction of fibrinogen with microglia supresses relapsing paralysis…”
BackgroundThe blood-brain barrier in cortical multiple sclerosis lesions
van Horssen, J., Brink, B. P., de Vries, H. E., van der Valk, P., & Bø, L. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318040b2de · Cited by 187 · cited 3×
“Regardless, our findings challenge the idea that large-molecular-weight serum proteins are not deposited in the progressive MS cortex.(5) The explanation for this inconsistency is not clear, but may relate to differences in tissue antigenicity that relate to fixation and/or processing protocols employed by different i…”
BackgroundInfluentialMicroglia change from a reactive to an age-like phenotype with the time in culture
Caldeira, C., Oliveira, A. F., Cunha, C., Vaz, A. R., Falcão, A. S., Fernandes, A., & Brites, D. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00152 · Cited by 156 · cited 1×
“Although we could not demonstrate a relationship between fibrin(ogen) deposition and innate inflammation in our cohort, such relationships may be difficult to discern given that genetic factors, disease evolution, and aging likely impact the recognized phenotypic heterogeneity of microglial/macrophage inflammation.(20…”
BackgroundLeech, S., Kirk, J., Plumb, J., & McQuaid, S. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00781.x · Cited by 137
Breaking boundaries—coagulation and fibrinolysis at the neurovascular interface
Bardehle, S., Rafalski, V. A., & Akassoglou, K. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00354 · Cited by 76
Cited by
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics
Petersen, M. A., Ryu, J. K., & Akassoglou, K. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2018.13 · Cited by 527
The immunology of multiple sclerosis
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A., & Fugger, L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00718-z · Cited by 380
Association between pathological and MRI findings in multiple sclerosis
Filippi, M., Brück, W., Chard, D., Fazekas, F., Geurts, J. J. G., Enzinger, C., Hametner, S., Kuhlmann, T., Preziosa, P., Rovira, À., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30451-4 · Cited by 253
Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration
Ryu, J. K., Rafalski, V. A., Meyer-Franke, A., Adams, R. A., Poda, S. B., Rios Coronado, P. E., Pedersen, L. Ø., Menon, V., Baeten, K. M., Sikorski, S. L., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0232-x · Cited by 213
Metadata
- Authors
- Yates, R. L., Esiri, M. M., Palace, J., Jacobs, B., Perera, R., & DeLuca, G. C.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2017-08
- Volume
- 82
- Issue
- 2
- Pages
- 259-270
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2738968781
- Cited by
- 112
- References
- 10
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. https://app.cochat.ai/papers/10.1002/ana.24997
- The paper
- Yates, R. L., Esiri, M. M., Palace, J., Jacobs, B., Perera, R., & DeLuca, G. C. (2017). Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. Annals of Neurology. https://doi.org/10.1002/ana.24997
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.